Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28147868 | 0.80 | MTNR1A (0.44) | LMNAKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL6428552 | 0.80 | PARP1 (0.48) | LMNAKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL28147782 | 0.80 | LMNA (0.43) | LMNAKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL31219282 | 0.80 | PARP1 (0.48) | LMNAKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL11667512 | 0.79 | LMNA (0.42) | LMNAKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL31185729 | 0.77 | L3MBTL1 (0.58) | KDM4EALDH1A1HPGDMAPTHSD17B10 | |
| SCHEMBL14246881 | 0.77 | L3MBTL1 (0.58) | KDM4EALDH1A1HPGDMAPTHSD17B10 | |
| SCHEMBL14387230 | 0.77 | LMNA (0.41) | LMNAKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL28237309 | 0.77 | LMNA (0.41) | LMNAKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL665931 | 0.77 | HTT (0.42) | LMNAKDM4EALDH1A1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6391917-B1 | ANALGESIC | ZYMOGENETICS, INC. | 2002-05-21 | — | — | US | claimed |
| US-6255351-B1 | TREATMENT OF BONE DISORDERS | ZYMOGENETICS, INC. | 2001-07-03 | — | — | US | claimed |
| US-6221913-B1 | Dialkyl ureas as calcitonin mimetics | ZYMOGENETICS, INC. | 2001-04-24 | — | — | US | claimed |
| EP-0975589-A2 | DIALKYL UREAS AS CALCITONIN MIMETICS | ZymoGenetics, Inc. (US) | 2000-02-02 | — | — | EP | claimed |
| WO-1999037604-A2 | DIALKYL UREAS AS CALCITONIN MIMETICS | ZYMOGENETICS, INC. (US) | 1999-07-29 | — | — | WO | claimed |
| EP-2762150-A1 | Treatment of Diabetes and Metabolic Syndrome | Nordic Bioscience A/S (DK) | 2014-08-06 | — | — | EP | disclosed |
| EP-2405934-B1 | Treatment of diabetes and metabolic syndrome | NORDIC BIOSCIENCE AS (DK) | 2014-03-26 | — | — | EP | disclosed |
| US-20120046224-A1 | TREATMENT OF DIABETES AND METABOLIC SYNDROME | NORDIC BIOSCIENCE A/S (DK) | 2012-02-23 | — | — | US | disclosed |
| EP-2405934-A1 | Treatment of diabetes and metabolic syndrome | Nordic Bioscience A/S (DK) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010103045-A1 | TREATMENT OF DIABETES AND METABOLIC SYNDROME | NORDIC BIOSCIENCE A/S (DK) | 2010-09-16 | — | — | WO | disclosed |
| US-6391917-B1 | ANALGESIC | ZYMOGENETICS, INC. | 2002-05-21 | — | — | US | disclosed |
| US-6255351-B1 | TREATMENT OF BONE DISORDERS | ZYMOGENETICS, INC. | 2001-07-03 | — | — | US | disclosed |
| US-6221913-B1 | Dialkyl ureas as calcitonin mimetics | ZYMOGENETICS, INC. | 2001-04-24 | — | — | US | disclosed |
| EP-0975589-A2 | DIALKYL UREAS AS CALCITONIN MIMETICS | ZymoGenetics, Inc. (US) | 2000-02-02 | — | — | EP | disclosed |
| WO-1999037604-A2 | DIALKYL UREAS AS CALCITONIN MIMETICS | ZYMOGENETICS, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046224-A1 | TREATMENT OF DIABETES AND METABOLIC SYNDROME | IAPP, GLP1R, CALCA | LMNA 2076/4885KDM4E 4840/4885ALDH1A1 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.